What vaccine makers are saying about B.1.1.529:
-Moderna notes it's shown it can get into clinic (human trials) within 60 days; question is regulatory process from there. Manufacturing new doses could take a few months.
-BioNTech expects lab data within 2 weeks (1/2)
-Moderna notes it's shown it can get into clinic (human trials) within 60 days; question is regulatory process from there. Manufacturing new doses could take a few months.
-BioNTech expects lab data within 2 weeks (1/2)
What vaccine makers are saying about B.1.1.529 (cont):
-lab data will tell BioNTech whether B.1.1.529 could be an escape variant
-Pfizer/BioNTech can adapt mRNA vaccine within 6 weeks, ship initial batches within 100 days in event of escape variant (2/2)
-lab data will tell BioNTech whether B.1.1.529 could be an escape variant
-Pfizer/BioNTech can adapt mRNA vaccine within 6 weeks, ship initial batches within 100 days in event of escape variant (2/2)
What vaccine makers are saying about B.1.1.529 (cont):
-J&J says it's closely monitoring new strains and is "already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in southern Africa." (3/2)
-J&J says it's closely monitoring new strains and is "already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in southern Africa." (3/2)
What vaccine makers are saying about B.1.1.529 - now Omicron (cont):
-Novavax "has already initiated development of a new recombinant spike protein based on the known genetic sequence ... and will have it ready to begin testing and manufacturing within the next few weeks." (4/2)
-Novavax "has already initiated development of a new recombinant spike protein based on the known genetic sequence ... and will have it ready to begin testing and manufacturing within the next few weeks." (4/2)
What vaccine makers are saying about Omicron (cont):
-Moderna announces 3-pronged strategy:
-evaluating full booster dose of original vaccine
-studying two multi-valent boosters
-advancing Omicron-specific booster
investors.modernatx.com/news-releases/… (5/2)
-Moderna announces 3-pronged strategy:
-evaluating full booster dose of original vaccine
-studying two multi-valent boosters
-advancing Omicron-specific booster
investors.modernatx.com/news-releases/… (5/2)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
